AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03057236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Coping Skills
Description: The CBCS-HCV is a psychosocial intervention delivered in group format. Through 9 group sessions, patients will learn coping skills, relaxation techniques and other new cognitive and behavioral skills based on several empirically-supported cognitive behavioral interventions.
Study NCT03443908 — intervention group
Intervention type: DEVICE
Intervention: CPAP
Description: CPAP therapy 3-4 weeks
Study NCT00822965 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: 3 sets of questionnaires at the beginning of the study, at 2-months and at 4-months.
Study NCT00822965 — intervention group
Intervention type: OTHER
Intervention: Phone Interviews
Description: 2 follow-up phone interviews.
Study NCT00822965 — intervention group
Intervention type: BEHAVIORAL
Intervention: Educational Packet
Description: Video or DVD of device information, updates, recalls, on-line resources and benefits of routine follow-up for device(s).
Study NCT00530894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN Transcatheter Heart Valve
Study NCT00530894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Valve Replacement
Study NCT00530894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical management and/or balloon aortic valvuloplasty
Study NCT01081912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, no active substance, shells identical to active comparator capsules
Study NCT01081912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone bitartrate
Description: dosage form: capsule~Strengths 10mg, 20mg, 30mg, 40mg, 50mg
Study NCT03578471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid without NR and BF
Description: Each participant will be fitted with the Noise Reduction (NR) and Beamforming (BF) disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
Study NCT03578471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR
Description: Each participant will be fitted with the Noise Reduction (NR)(Sound Changing) program on the same hearing aid. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The Noise Reduction is working spatially independent.
Study NCT03578471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with BF
Description: Each participant will be fitted with a beam forming program on the same hearing aid. Beam forming (BF) principle is a sound processing algorithm to remove noise from certain directions to improve the speech intelligibility and comfort.
Study NCT02340585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next Generation Neuroform Stent System
Description: The Next Generation Neuroform Stent System is pre-loaded on a stent delivery wire and protected by a transfer sheath. An accessory pouch containing an optional stabilizer may be attached to the proximal end of the stent delivery wire to facilitate handling and stabilization.
Study NCT01418807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRANSVAGINAL SPECIMEN EXTRACTION
Description: Transvaginal specimen retrieval following posterior colpotomy
Study NCT01418807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRANSUMBILICAL SPECIMEN EXTRACTION
Description: Transumbilical specimen retrieval following enlargement of the umbilical port
Study NCT02238275 — intervention group
Intervention type: DRUG
Intervention: Micardis® plus
Study NCT02330159 — intervention group
Intervention type: PROCEDURE
Intervention: Novel Wound Healing Protocol
Description: All patients will undergo surgical excision of the pilonidal disease and application of the novel wound healing protocol. After excision, MatriStem MicroMatrix powder will be applied to the wound bed. A MatriStem Multilayer Wound Matrix sheet will then be placed over the MatriStem MicroMatrix, secured in place, then covered with surface dressings. The wound should be left undisturbed for 10-14 days (until the 1st follow-up visit). At the 1st postoperative visit, the wound will reassessed, and a second application of the MicroMatrix to the wound bed may be performed. At subsequent follow-up visits at 1, 3, and 6 months, the wound bed will be measured, photo documentation will be captured, and patients will complete a survey to assess quality of life.
Study NCT01263483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and voglibose
Description: Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
Study NCT01263483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and voglibose
Description: Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
Study NCT01263483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voglibose
Description: Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
Study NCT01028092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti R-IL2 + Cyclosporine
Description: * anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~* cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6
Study NCT01028092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin + Everolimus
Description: * Thymoglobulin ® induction started at 1.5mg/kg/j then adjusted to CD2 or total lymphocytes count, for 5 days~* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~* everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6
Study NCT01028092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti R-IL2 + Cyclosporine then Everolimus
Description: * anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~* Mycophenolate Mofetil (Cellcept ®) 3 g/d beginning at D0~* cyclosporine A (Neoral ®) beginning at 6 to 8 mg/kg adjusted to C2, then switch to everolimus (Certican ®) between at W6, started at 3 mg/d, then adjusted to achieve a residual level between 6 et 10 ng/ml~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6
Study NCT03868592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric sleeve/bariatric surgery
Description: weight loss
Study NCT03087630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reasoned-Based Intervention
Description: Receives personalized feedback based on the reasoned pathway of the Prototype Willingness Model.
Study NCT03087630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social-Based Intervention
Description: Receives personalized feedback based on the social pathway of the Prototype Willingness Model.
Study NCT03087630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Intervention
Description: Receives personalized feedback based on both the reasoned and social pathways of the Prototype Willingness Model.
Study NCT03087630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control
Description: Receives personalized feedback related to nutrition and exercise, unrelated to drinking behavior.
Study NCT00714285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' quadrivalent influenza vaccine
Description: Single intramuscular dose on Day 0.
Study NCT00714285 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' trivalent influenza vaccine
Description: Single intramuscular dose on Day 0.
Study NCT00131248 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ranitidine
Study NCT00131248 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Study NCT02281916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P28GST
Description: 3 injections of 100 µg of P28GST within 3 months (one injection per month)
Study NCT02030652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent nasal positive pressure positive ventilation.
Study NCT02005809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: second look endoscopy
Description: Second look endoscopy includes observation or prophylactic bleeding control of ESD site.
Study NCT03551223 — intervention group
Intervention type: BIOLOGICAL
Intervention: Neuron specific enolase (NSE)
Description: 5 cc of venous blood will be drawn from all of the participants and be examined for NSE and S100 B serum levels in order to evaluate evaluate which anesthetic method (general anesthesia versus spinal anesthesia) is associated with reduced neuronal injury in a preeclamptic parturients undergoing a cesarean section.
Study NCT02030652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Nasal continuous positive airway pressure
Study NCT00649207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888
Description: Oral Capsules
Study NCT00649207 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiation Therapy
Description: 15 fractions of 2.5 Gy over 3 weeks to a total dose of 37.5 GY or 10 fractions of 3.0 Gy over 2 weeks to a total dose of 30 Gy
Study NCT02504151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Study NCT02504151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04522232 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional Total laparoscopic hysterectomy
Description: the ascending branch of the uterine artery was identified close to the isthmus then ligated at this level, close to the uterus or coagulated, using bipolar diathermy. The utero-vesical fold was dissected and the bladder was pushed down done, thus moving the ureters laterally, which decreases the risk of including them in a suture. The vasculature of the uterus is now secured and this is evidenced by the pale color of the fundus.~Using either bipolar diathermy or the harmonic ultracision, the cornual pedicles on one side were desiccated and cut. Also, both the uterosacral and cardinal ligaments were desiccated and cut. So that, the opposite side pedicles can be taken care of, the direction of manipulator was changed. The infundibulopelvic ligaments were desiccated and cut if it is necessary to remove both ovaries. A vaginal cuff was inserted into the vagina to identify the vault, which was then cut laparoscopically using a monopolar hook, where the specimen was completely detached.
Study NCT04522232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy with prior uterine artery ligation at its origin
Description: the uterine artery was dissected using the lateral approach; where dissection begins from the anterior leaf of the broad ligament. The triangle enclosed by the round ligament, external iliac artery, and infundibulopelvic ligament was opened. The areolar space was dissected and the origin of the uterine artery from the internal iliac and the ureter was identified. The uterine artery was then isolated from the surrounding structures and ligated by Hem-o-lok clips.~then same steps as conventional Total laparoscopic hysterectomy
Study NCT01702649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPX2003 (Biapenem)
Description: Six (6) cohorts of 3 active or 8 subjects of 6 active are planned for evaluation.~Single dose followed by multiple dose, three times a day.
Study NCT01702649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six (6) cohorts of 1 placebo or 8 subjects of 2 placebo are planned for evaluation.~Single dose followed by multiple dose, three times a day.
Study NCT01812252 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azacitidine (AZC)
Description: Given IV or SC
Study NCT01812252 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: Given IV or SC
Study NCT01812252 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01957007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered IV.
Study NCT03077347 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
Study NCT02989558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor plus ASA
Description: Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
Study NCT02989558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel plus ASA
Description: Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
Study NCT04309240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 10mg orally per day for 90days
Study NCT02229500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Study NCT02229500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2.5 g of propionate
Description: This system delivers approximately 2.5 g of propionate to the colon in a 10g dose.
Study NCT02229500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5 g of propionate
Description: This delivers approximately 5g of propionate to the colon per 10g dose
Study NCT03306732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine hydrochloride (200mg) dissolved in 100 ml of normal saline
Description: * After anesthesia induction~* After separation from CPB~* On the evening of the day of surgery (22:00)~* On POD 1 twice a day at 8:00 and 22:00~* On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~* On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)
Study NCT03306732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (100ml)
Description: * After anesthesia induction~* After separation from CPB~* On the evening of the day of surgery (22:00)~* On POD 1 twice a day at 8:00 and 22:00~* On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~* On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)
Study NCT03243383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DiaTOHC Program
Description: 1. Patient-centered education 1a) Standardized diabetes discharge instructions and education 1b) Comprehensive discharge plan review~2. Peri-discharge coordination of care~3. A1c-based adjustment of diabetes therapy~4. Post-discharge support
Study NCT00630656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talactoferrin alfa
Description: 15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
Study NCT00630656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
Study NCT02167750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cherry Flavored Beverage
Description: Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.
Study NCT02167750 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cherry Flavored Beverage
Description: Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.
Study NCT04670614 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nerve Block with ropivicaine 0.5% Injectable Solution
Description: Peripheral nerve blocks using 0.5% ropivicaine
Study NCT04670614 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Nerve Block with Placebo sham control of 0.9% Normal Saline
Description: Peripheral Nerve Block with placebo 0.9% normal saline
Study NCT02963389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripegfilgrastim
Study NCT02410668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flaxseed
Study NCT02410668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02410668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise recommendation
Study NCT02410668 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise recommendation
Study NCT01796587 — intervention group
Intervention type: DEVICE
Intervention: LoFric Origo
Study NCT03374189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EZ close
Description: EZ close used.
Study NCT03374189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carter Thomason
Description: Carter Thomason used.
Study NCT01356407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PICOPREP
Study NCT01356407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-ELS
Study NCT01957007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vantictumab
Description: Vantictumab will be administered intravenously
Study NCT01826279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 500mg 3 times daily for 1 month
Study NCT01826279 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo tablet 3 times daily for 1 month
Study NCT04585464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDG-5506
Description: EDG-5506 is administered orally as a single dose or once daily
Study NCT04585464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally as a single dose or once daily
Study NCT04351984 — intervention group
Intervention type: DEVICE
Intervention: MitraClip
Description: Transcatheter Mitral Valvuloplasty with MitraClip
Study NCT01059669 — intervention group
Intervention type: OTHER
Intervention: diagnostic test
Study NCT02947035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thyroid lobectomy
Description: Thyroid lobectomy is removal of only part of the thyroid
Study NCT02947035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy with CCND
Description: Total thyroidectomy with central compartment lymph node dissection is removal of the entire thyroid with the surrounding lymph nodes
Study NCT02690155 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: As prescribed by treating physicians
Study NCT02690155 — intervention group
Intervention type: DRUG
Intervention: VKA (Vitamin K antagonist)
Description: As prescribed by treating physicians
Study NCT04502251 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Low-Dose Naltrexone
Description: 4.5mg daily dose, orally, during 26 days
Study NCT04502251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose Naltrexone
Description: 4.5mg daily dose, orally, during 26 days
Study NCT04502251 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: An anodal electrode was placed on the scalp above the primary motor cortex (M1), contralateral to the dominant cortex. The cathodal electrode was placed on the supraorbital contralateral area. The current used was 2mA during 20 minutes.
Study NCT04502251 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: An anodal electrode was placed on the scalp above the primary motor cortex (M1), contralateral to the dominant cortex. The cathodal electrode was placed on the supraorbital contralateral area. The current used was 2mA during 20 minutes.
Study NCT04502251 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The capsule presented the same format, size and color as LDN capsules, however the excipient used was starch.
Study NCT04502251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The capsule presented the same format, size and color as LDN capsules, however the excipient used was starch.
Study NCT04502251 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Sham-tDCS stimulation consists of an active current during 30 seconds
Study NCT04502251 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sham Transcranial Direct Current Stimulation
Description: Sham-tDCS stimulation consists of an active current during 30 seconds